Centaurus Financial Inc. Buys New Stake in Lantheus Holdings, Inc. $LNTH

Centaurus Financial Inc. purchased a new position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 6,015 shares of the medical equipment provider’s stock, valued at approximately $667,000.

Other hedge funds have also made changes to their positions in the company. ABS Investment Management LLC acquired a new stake in Lantheus during the second quarter worth approximately $232,974,000. Versant Capital Management Inc raised its stake in Lantheus by 33.0% during the 2nd quarter. Versant Capital Management Inc now owns 588 shares of the medical equipment provider’s stock worth $65,000 after acquiring an additional 146 shares in the last quarter. Abel Hall LLC raised its stake in Lantheus by 4.6% during the 1st quarter. Abel Hall LLC now owns 3,915 shares of the medical equipment provider’s stock worth $297,000 after acquiring an additional 172 shares in the last quarter. Smartleaf Asset Management LLC lifted its position in Lantheus by 63.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock valued at $34,000 after acquiring an additional 197 shares during the last quarter. Finally, GAMMA Investing LLC lifted its position in Lantheus by 6.4% in the second quarter. GAMMA Investing LLC now owns 3,348 shares of the medical equipment provider’s stock valued at $371,000 after acquiring an additional 202 shares during the last quarter. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on LNTH shares. Citizens Jmp reissued a “market outperform” rating and issued a $115.00 target price on shares of Lantheus in a research report on Monday, June 29th. William Blair set a $102.50 price objective on Lantheus in a research note on Monday, August 3rd. Mizuho decreased their price objective on Lantheus from $120.00 to $115.00 and set an “outperform” rating for the company in a report on Wednesday, July 29th. The Goldman Sachs Group restated a “neutral” rating and set a $94.00 target price on shares of Lantheus in a research report on Thursday, May 7th. Finally, Citigroup reaffirmed an “outperform” rating on shares of Lantheus in a report on Friday, May 8th. Four research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $108.11.

Lantheus Stock Up 0.3%

LNTH opened at $100.77 on Friday. Lantheus Holdings, Inc. has a 52 week low of $49.67 and a 52 week high of $111.86. The business has a 50 day moving average price of $103.74 and a two-hundred day moving average price of $91.58. The company has a quick ratio of 2.89, a current ratio of 3.06 and a debt-to-equity ratio of 0.43. The company has a market cap of $6.58 billion, a PE ratio of 24.34 and a beta of -0.03.

Lantheus (NASDAQ:LNTH) last announced its earnings results on Thursday, August 6th. The medical equipment provider reported $1.55 earnings per share for the quarter, beating the consensus estimate of $1.30 by $0.25. Lantheus had a return on equity of 28.10% and a net margin of 17.69%.The company had revenue of $388.18 million for the quarter, compared to the consensus estimate of $363.23 million. During the same period last year, the business posted $1.57 EPS. The company’s revenue was up 2.7% on a year-over-year basis. As a group, research analysts anticipate that Lantheus Holdings, Inc. will post 4.48 EPS for the current year.

Lantheus Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.